← Back to Clinical Trials
Recruiting NCT07410325

NCT07410325 Effectiveness and Implementation of a Community-based Health Coach-led Artificial Intelligence (AI)-Powered Digital Self-Regulation Program for Individuals With Metabolic Syndrome (MetS)

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07410325
Status Recruiting
Phase
Sponsor National University Health System, Singapore
Condition Metabolic Syndrome (MetS)
Study Type INTERVENTIONAL
Enrollment 316 participants
Start Date 2026-01-01
Primary Completion 2027-01

Eligibility & Interventions

Sex All sexes
Min Age 21 Years
Max Age 65 Years
Study Type INTERVENTIONAL
Interventions
LIGHTER-MetS

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 316 participants in total. It began in 2026-01-01 with a primary completion date of 2027-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study aims to evaluate the effectiveness of the Lifestyle Intervention for Gentle, Healthy Transformation and Enhanced Weight Reduction-metabolic syndrome (LIGHTER-MetS) program on dietary self-regulation and cardiovascular risk among individuals with metabolic syndrome (MetS). The LIGHTER-MetS program, a community-based, grassroots-led initiative, integrates health coaching with the eTRIP© app to promote sustainable lifestyle changes focusing on diet, exercise, and emotion regulation.

Eligibility Criteria

Inclusion Criteria: 1. are between 21 to 65 years of age; 2. have a waist circumference ≥90 cm in men and ≥80 cm in women; 3. have 2 or more of the following to be classified as having metabolic syndrome: * triglyceride level of ≥1.7 mmol/L or on specific treatment for this lipid abnormality; * high density lipoprotein (HDL) cholesterol \<1.03 mmol/L in men, and \<1.29 mmol/L in women, or on specific treatment for this lipid abnormality; * blood pressure of ≥130/85 mmHg or on treatment of previously diagnosed hypertension; * fasting blood glucose level of ≥ 5.6 mmol/L or previously diagnosed type 2 diabetes; 4. are not receiving other structured lifestyle modification programs; 5. consent to audio-recording; 6. English speaking and literate. Exclusion Criteria: 1. underwent or are scheduled for metabolic surgery within 1 year; 2. are pregnant or planning for pregnancy at the time of recruitment; 3. are unable to speak English; 4. do not own a smartphone; and 5. are unable to provide informed consent.

Contact & Investigator

Central Contact

Jocelyn Chew

✉ dbi-lab@nus.edu.sg

📞 +6565168687

Frequently Asked Questions

Who can join the NCT07410325 clinical trial?

This trial is open to participants of all sexes, aged 21 Years or older, up to 65 Years, studying Metabolic Syndrome (MetS). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07410325 currently recruiting?

Yes, NCT07410325 is actively recruiting participants. Contact the research team at dbi-lab@nus.edu.sg for enrollment information.

Where is the NCT07410325 trial being conducted?

This trial is being conducted at Singapore, Singapore.

Who is sponsoring the NCT07410325 clinical trial?

NCT07410325 is sponsored by National University Health System, Singapore. The trial plans to enroll 316 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology